Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Br J Haematol. 2023 Dec;203(5):840-851. doi: 10.1111/bjh.19055. Epub 2023 Aug 24.
Comorbidity assessment before allogeneic haematopoietic cell transplantation (allo-HCT) is essential for estimating non-relapse mortality (NRM) risk. We previously developed the Simplified Comorbidity Index (SCI), which captures a small number of 'high-yield' comorbidities and older age. The SCI was predictive of NRM in myeloablative CD34-selected allo-HCT. Here, we evaluated the SCI in a single-centre cohort of 327 patients receiving reduced-intensity conditioning followed by unmanipulated allografts from HLA-matched donors. Among the SCI factors, age above 60, mild renal impairment, moderate pulmonary disease and cardiac disease were most frequent. SCI scores ranged from 0 to 8, with 39%, 20%, 20% and 21% having scores of 0-1, 2, 3 and ≥4 respectively. Corresponding cumulative incidences of 3-year NRM were 11%, 16%, 22% and 27%; p = 0.03. In multivariable models, higher SCI scores were associated with incremental risks of all-cause mortality and NRM. The SCI had an area under the receiver operating characteristic curve of 65.9%, 64.1% and 62.9% for predicting 1-, 2- and 3-year NRM versus 58.4%, 60.4% and 59.3% with the haematopoietic cell transplantation comorbidity index. These results demonstrate for the first time that the SCI is predictive of NRM in patients receiving allo-HCT from HLA-matched donors after reduced-intensity conditioning.
在进行异基因造血细胞移植(allo-HCT)之前,对合并症进行评估对于估计非复发死亡率(NRM)风险至关重要。我们之前开发了简化合并症指数(SCI),该指数可捕获少数“高产量”合并症和年龄较大。在清髓性 CD34 选择 allo-HCT 中,SCI 可预测 NRM。在这里,我们在接受强度降低的条件预处理后接受 HLA 匹配供体未处理同种异体移植物的 327 例患者的单中心队列中评估了 SCI。在 SCI 因素中,年龄超过 60 岁,轻度肾功能不全,中度肺部疾病和心脏病最为常见。SCI 评分范围为 0 至 8,分别有 39%,20%,20%和 21%的评分分别为 0-1,2,3 和≥4。相应的 3 年 NRM 的累积发生率分别为 11%,16%,22%和 27%;p=0.03。在多变量模型中,较高的 SCI 评分与全因死亡率和 NRM 的增量风险相关。与移植后血液学并发症指数相比,SCI 预测 1 年,2 年和 3 年 NRM 的受试者工作特征曲线下面积分别为 65.9%,64.1%和 62.9%,为 58.4%,60.4%和 59.3%。这些结果首次表明,SCI 可预测接受强度降低条件预处理后接受 HLA 匹配供体 allo-HCT 的患者的 NRM。